TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03501368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Participants will take ceritinib by mouth (PO) once daily at a dose of up to 450 mg (3 capsules of 150 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Participants will take trametinib by mouth at a dose of 2 mg daily
Study: NCT01091103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study: NCT04174352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: estrogen modulator

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FES PET/CT
Description: Radiolabeled estrogen \[18F\]-fluoroestradiol (FES) in combination with Positron Emission Tomography / Computed Tomography is a molecular imaging technique for measuring pharmacodynamic effects of endocrine therapy. The injected dose of 18F-FES will be 6 mCi (185 MBq) ± 20% with a specific activity greater than 170 Ci/mmol at the time of injection for an activity dose of 6 mCi. Participant will receive baseline imaging and repeat imaging after 3-4 weeks to evaluate for FES blockade as assigned dose level.
Study: NCT01701388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso exoskeleton
Description: The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.
Study: NCT03878524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT04131231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: microparticles packaging methotrexate (MPs-MTX)
Description: 50ml, intrapleural infusion, day5,6,7,8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human interleukin-2(rhIL-2)
Description: 50ml, intrapleural infusion, day5,8,11
Study: NCT02150759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine infusion during spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine infusion during spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: add dexmedetomidine during position change

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: add dexmedetomidine during position change
Study: NCT01609621

Intervention type: DEVICE
Intervention: Retrograde tibiopedal arterial access
Description: Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
Study: NCT03927924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound
Description: Energy employed to exert its effect through thermal and mechanical destruction of cancer tissue
Study: NCT02704234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Acupuncture
Description: Active Acupuncture two times per week for 5 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupuncture
Description: Placebo Acupuncture two times per week for 5 weeks
Study: NCT02332980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03878524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given PO
Study: NCT02332980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02728765

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
Study: NCT03878524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06490003

Intervention type: DRUG
Intervention: Fluoro Uracil
Description: Esophageal cancer chemotherapy（First line treatment)

Intervention type: DRUG
Intervention: Fluoro Uracil
Description: Esophageal cancer chemotherapy（First line treatment)
Study: NCT02234206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chandrakanthi Choornam (CKC)
Description: 12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration~Preparation from approved sastric book as per drugs \& cosmetic act 1940
Study: NCT01709734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galeterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galeterone
Study: NCT01417819

Intervention type: OTHER
Group type: OTHER
Intervention: Mobile short message service
Description: Mobile short message service reminder for appointments of parents of cataract children
Study: NCT03043118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variety Intervention
Description: Vegetable flavor variety created with multiple herb and spice blends
Study: NCT03878524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given IV
Study: NCT03308032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: SDL intervention employs a comprehensive engagement design that includes seven innovative strategies: 1) customization of content of the training curriculum to fit individual learner's needs; 2) tailoring the length of trainings by using short video clips to allow caregivers flexibility in completing the curriculum; 3) using an instructional format (SCHOLAR) designed to maximize active learning during each training lesson; 4) progress tracking to help the learner stay focused and motivated; 5) a recommendation algorithm that facilitates the learner's transition from one training topic to the next; 6) behavioral economics-based messages, to re-engage the learner if he/she stops participating

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control group will be invited to a comparable online training course consisting of all of our training video clips, without the interactive engagement design features. These represent standard video training based on evidence-based content.
Study: NCT00816920

Intervention type: OTHER
Intervention: Ultrasound examination of leg veins
Description: Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
Study: NCT03641339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One vector feeding
Description: Participants will undergo one feeding by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Four vector feeding
Description: Participants will undergo four feedings by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies), each about 2 weeks apart, with the same vector type.
Study: NCT02527135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly HIV sensitization text messages
Description: Weekly HIV sensitization text messages with option to text back up to 3 times per week for additional messages. Message topics included pregnancy, condoms, sexually transmitted infections, contraceptives, anal sex and personal risk of HIV. All messages ended with the phrase Get tested for HIV.
Study: NCT01837108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02728765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
Study: NCT04597203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755-nm picosecond alexandrite laser with topical 2% hydroquinone
Description: treatment one side of the face with 755-nm picosecond alexandrite laser with topical 2% hydroquinone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical 2% hydroquinone
Description: treatment one side of the face with topical 2% hydroquinone
Study: NCT02257008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapefruit juice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Study: NCT03878524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study: NCT02257008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT00411528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study: NCT03187860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial Biopsy
Description: Bronchial biopsies will be performed on all subjects.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial Biopsy
Description: Bronchial biopsies will be performed on all subjects.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial Biopsy
Description: Bronchial biopsies will be performed on all subjects.
Study: NCT00411528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Study: NCT03878524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT00287859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
Study: NCT04400760

Intervention type: DRUG
Group type: OTHER
Intervention: DAPA Tx
Description: The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
Study: NCT01492972

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Consists of:~1. Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~2. High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~3. Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Consists of:~1. Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~2. High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~3. Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Suppression Therapy
Description: Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
Study: NCT02504346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Study: NCT03697850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy
Study: NCT03838744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard arm: Trabectedin in monotherapy
Description: Trabectedin in monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental arm: Trabectedin + Olaparib
Description: Trabectedin given in combination to olaparib
Study: NCT02202564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LT
Description: Orthotopic LT
Study: NCT01644539

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Water with guar gum - Non Caloric
Description: Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
Study: NCT02202564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LT
Description: Orthotopic LT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV-TK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganciclovir
Study: NCT01644539

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Chocolate milk - Oral Caloric
Description: Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Chocolate milk - Intra Gastric Caloric
Description: Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
Study: NCT01463488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113945
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113945
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Study: NCT04505761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants will use a Virtual Reality headset with a range of applications applicable for rehabilitation after COVID-19. Applications target physical, psychological, and cognitive rehabilitation. VR headset will be used for six weeks first at the physiotherapist's practice, and when possible, at home.
Study: NCT03401203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy followed by balloon angioplasty
Description: Percutaneous coronary intervention
Study: NCT01463488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113945
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Study: NCT03401203

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon angioplasty
Description: Percutaneous coronary intervention
Study: NCT06268470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine plus cilostazol and dipyridamole
Description: Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine 20 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine 20 mg/day
Study: NCT03764969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard smoking cessation program (SCP)
Description: Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer 2004), and will be carried out by a qualified therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard smoking cessation program (SCP)
Description: Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer 2004), and will be carried out by a qualified therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard smoking cessation program (SCP)
Description: Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer 2004), and will be carried out by a qualified therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation treatment (CRT)
Description: Cognitive remediation treatment (CRT) employing a chess-based battery of tasks two times per week over six weeks as a group treatment in our outpatient clinic (60 min duration per session).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implicit computer-based habit-modifying training (ICHT)
Description: Implicit computer-based habit-modifying training (ICHT), applied twice a week for six weeks. In this training, the participants perform a two-part training. First, a subliminal presentation (20 ms) of negative valenced primes before smoking-cues in context and secondly, a subliminal presentation of positive valenced primes before potentially reinforcing events.
Study: NCT00165828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonegran
Description: Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonegran
Description: Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
Study: NCT02466724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aiddly (Web Site)
Description: A website designed to better educate patients on how to prepare for their colonoscopies
Study: NCT03720366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enasidenib
Description: enasidenib
Study: NCT01463488

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Study: NCT01596478

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
Study: NCT03720366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enasidenib
Description: enasidenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enasidenib
Description: enasidenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 probes
Description: caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole
Study: NCT01405118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/CP-690,550
Description: Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.